immunoSEQ Blog

IGH Sequencing- Entire or Partial VDJ?

Q: What does IGH sequencing cover? Entire or partial VDJ? A: The IGH assay covers 130 nucleotides in total, including all of the CDR3 region. It contains about 80-100 bases of V and ends about 20 bases into the J gene segment (if you load the full sequence in our “Sequence Detail” tool). This is not… Read More→

Categorized in: Questions & Answers |

Adaptive Data to be Presented at the Society of Investigative Dermatology Meeting May 7-10

Screen Shot 2014-04-23 at 10.33.36 AM

The Adaptive Biotechnologies platform of T-cell receptor profiling will be presented in two talks to be given at this year’s Annual Meeting of the Society of Investigative Dermatology, to be held in Albuquerque, New Mexico from May 7-10. These talks will highlight the added value of the Adaptive platform for assisting in the diagnosis and… Read More→

Categorized in: Announcements |

Adaptive CEO Highlighting Companies’ Work in Cancer Immunotherapy at the “What’s Hot in Cancer Immunotherapy” Event at the Fred Hutchinson Cancer Research Center

Screen Shot 2014-04-22 at 11.48.28 AM

Today, Adaptive Biotechnologies Corporation CEO, Chad Robins, will be highlighting the companies’ work in cancer immunotherapy at the “What’s Hot in Cancer Immunotherapy” event hosted by Xconomy at the Fred Hutchinson Cancer Research Center. Mr. Robins will focus on Adaptive Biotechnologies’ state-of-the-art immune sequencing assays that are being used to discover and develop applications for… Read More→

Categorized in: Announcements |

Adaptive Customers Publish Latest Results

Last Friday, a team of researchers from Princeton, CNRS and Ecole Normale Superieure and Stanford University published results from a study in which they used the immunoSEQ assay to sequence T cell repertoires from 9 human subjects to study selection effects. The study resulted in the findings that selection varies little between individuals or between… Read More→

Categorized in: Announcements |

Immune Systems of Twins: Not So Similar After All?

It’s been more than a year since this blog last hosted a discussion on the utility of twin studies for understanding the genetic vs. environmental contributions to the development of the adaptive immune system.  A recent publication in The Proceedings of the National Academy of Sciences offers an opportunity for a timely update on this subject. In… Read More→

Categorized in: Food for Thought |

20-year Biotech Outlook and the Big Data Opportunity

Our friends over at Xconomy recently held a panel discussion on the 20-year outlook for the San Diego life sciences industry. On the panel were John Mendlein of San Diego-based Fate Therapeutics, Paul Schimmel of The Scripps Research Institute, Dan Bradbury of Amylin Pharmaceuticals, and Rusty Gage of the Salk Institute for Biological Studies. Some… Read More→

Categorized in: Food for Thought |

A ‘Build Your Own’ Anti-virus Immune System?

It’s not that simple, but scientists from the Singapore Institute for Clinical Sciences and colleagues recently published a report in Nature about the creation of a Virus-specific T Cell Receptor Library to target viral infections. The team sorted T cells from donors with specific antibodies and amplified TCR alpha and beta genes. After cloning, they… Read More→

Categorized in: Food for Thought |

Comparing Sequencing Data to Outside Sequences

Q: I recently sent in tumor samples and just got my results. Is there a way to compare the sequences of the clones to the sequence of the tumor? The tumor sequence is available in genbank but I’m not sure where in the analysis software I can upload this sequence for comparison. A: ImmunoSEQ doesn’t have… Read More→

Categorized in: Questions & Answers |

PDL1 Expression: Marker or Not?

All eyes are watching five pharmaceutical companies race to develop and launch a PD1 or PDL1 inhibitor in various tumor types.  Attempting to screen for high PD1 or PDL1 expression as a strategy to enrich patient populations has been tested to predict efficacy/segment patients. To date, while the data for these drugs looks very promising,… Read More→

Categorized in: Food for Thought |